Galen Growth Report Reveals Next Chapter for Femtech: Growth, Gaps, and New Potential in Women’s Health

CHICAGO--(BUSINESS WIRE)--Galen Growth, the leading digital health intelligence firm, has unveiled its 2025 FemTech report: “Femtech 2.0: Doubling Down on Growth”, spotlighting a sector at a turning point. While venture activity has expanded 3.2x during the past decade, outpacing the broader digital health ecosystem, Femtech grapples with persistent disparities in funding, clinical inclusion and systemic integration.

However, the report underscores the $360 billion opportunity in women’s health, which the industry has dubbed a “ghost market.” From overlooked chronic diseases to underfunded maternal care, data show that the digital health revolution is only just beginning to deliver on its promise for women.

Momentum and Stark Disparities

Despite a 2024 record $2.2 billion in Femtech funding, investment growth (1.4x over 10 years) continues to lag behind other health categories (3.2x) and deal-making momentum (partnerships up 15.3x).

Key findings:

• 71% of early-stage Femtech ventures struggle to raise a Series A round
• Cardiovascular disease, the leading cause of death among women, remains underrepresented in venture portfolios
• Clinical evidence requirements are nearly twice as stringent for Femtech ventures compared to the digital health average

“Femtech is no longer a fringe movement – it’s an essential component of public health and economic equity,” said Julien de Salaberry, Founder and CEO at Galen Growth. “But to fully realize its impact, we need to see a shift from D2C apps to integrated, reimbursable solutions in mainstream health systems.”

Femtech 2.0: Beyond Fertility and Fitbits

It is a new era of Femtech defined by AI-powered diagnostics, menopause care, and remote patient monitoring – areas historically neglected by traditional healthcare frameworks.

Key findings:

• Gynaecology and oncology account for more than half of Femtech ventures
• Health system partnerships comprise 23% of all Femtech collaborations, overtaking pharma and big tech for the first time
• Europe leads in clinical rigor, with 50% of ventures demonstrating proven clinical strength

Still, structural challenges persist. Without set reimbursement models, payer integration, or employer adoption, many ventures risk becoming luxury solutions for the prosperous few.

Looking Ahead

Success during the next five years will hinge on five elements: 1. redefining Femtech's scope; 2. breaking free from D2C constraints; 3. aligning evidence expectations; 4. unlocking growth-stage funding, and 5.sector consolidation through M&A.

“With nearly half of the global workforce made up of women, the return on investment in women’s health isn’t just moral – it’s macroeconomic,” de Salaberry added. “Femtech isn’t a trend. It’s infrastructure.”

About Galen Growth

Founded in 2016, Galen Growth partners with leading companies for their digital health market intel and insights needs. With comprehensive data, empirical research, and expert insights, the company helps global organizations find optimal solutions for their business transformation, discover the latest trends in digital health, and strengthen their innovative know-how. HealthTech Alpha, Galen Growth's proprietary platform, is the world's leading digital health private market platform, powering how leaders and corporations make digital health decisions.

Headquartered in Singapore, Galen Growth has offices in Basel (Switzerland), Boston and Chicago.

Please find us at galengrowth.com and follow us on X at @galengrowth and LinkedIn: https://www.linkedin.com/company/galen-growth/.